2022
310 Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naïve patients with moderate-to-severe atopic dermatitis
Gooderham M, Strober B, Ardern-Jones M, Guttman-Yassky E, Levenberg M, Chan G, Biswas P, Watkins M. 310 Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naïve patients with moderate-to-severe atopic dermatitis. Journal Of Investigative Dermatology 2022, 142: s53. DOI: 10.1016/j.jid.2022.05.318.Peer-Reviewed Original Research
2021
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
Lockshin B, Cronin A, Harrison R, McLean R, Anatale‐Tardiff L, Burge R, Zhu B, Malatestinic W, Atiya B, Murage M, Gallo G, Strober B, Van Voorhees A. Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry. Dermatologic Therapy 2021, 34: e14808. PMID: 33491259, PMCID: PMC8047872, DOI: 10.1111/dth.14808.Peer-Reviewed Original ResearchConceptsCorrona Psoriasis RegistryIL-17 inhibitorsIL-17iTNF inhibitorsReal-world patientsDrug survivalHazard ratioPsoriasis RegistryDrug discontinuationDrug initiationLower riskBiologic experienceIxekizumab groupsPsO patientsSevere PsONaïve patientsMean ageIxekizumabPatientsReal-world settingDiscontinuationPsoriasisSurvivalRegistryInhibitors